Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Molecular Partners, Allergan Form Pacts

by Ann M. Thayer
August 27, 2012 | A version of this story appeared in Volume 90, Issue 35

Molecular Partners and Allergan have two new agreements to discover and develop products for ophthalmic diseases. Allergan will pay the Swiss biotech firm $62.5 million up front and up to $1.4 billion in milestone payments. Molecular Partners develops small-protein drug candidates it calls DARPins. It will design a dual anti-VEGF-A/PDGF-B DARPin and related candidates for treating exudative age-related macular degeneration. The partners also will collaborate on finding DARPins against other eye-disease targets.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.